Drug intelligence / Profile preview

EN-2642

Development stage: Preclinical
Lead developer: Enosi Life Sciences
Modality: Small Molecules

Overview

EN-2642 is a preclinical-stage small molecule therapeutic agent being developed by Enosi Life Sciences Corp. It features a dual-mechanism of action, functioning as both an epidermal growth factor receptor (EGFR) inhibitor and a human epidermal growth factor receptor 3 (HER3) antagonist. This dual-targeting approach is designed to address the limitations of traditional EGFR-targeted therapies, particularly the development of resistance mediated by HER3 signaling pathways. The drug is currently being investigated for its potential in treating various cancers where these pathways are overexpressed or mutated.

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on EN-2642.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EN-2642.

Explore the full profile